LZYY(SH:603368)2020-10-27 16:00Financial Performance - Net profit attributable to shareholders was ¥608,479,200.09, reflecting an increase of 11.13% year-on-year[16]. - Operating revenue for the period was ¥11,754,356,956.09, representing a growth of 5.82% compared to the same period last year[16]. - Basic earnings per share increased to ¥1.68, up 11.26% from ¥1.51 in the same period last year[16]. - The company reported a net profit for Q3 2020 of ¥225,636,239.02, compared to ¥211,797,960.84 in Q3 2019, representing a growth of 6.5%[47]. - The company's net profit attributable to shareholders for Q3 2020 was ¥213,605,086.38, an increase from ¥191,369,827.37 in Q3 2019, representing a growth of approximately 6.43%[53]. - The company's operating profit for Q3 2020 was ¥245,057,727.07, compared to ¥145,238,452.34 in Q3 2019, indicating a significant increase of approximately 68.73%[57]. - The total comprehensive income for Q3 2020 was ¥225,636,239.02, compared to ¥211,797,960.84 in Q3 2019, which is an increase of about 6.54%[53]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥14,253,218,951.28, an increase of 19.19% compared to the end of the previous year[16]. - Total assets increased to CNY 14.25 billion, up from CNY 11.96 billion year-over-year, representing a growth of approximately 19.1%[39]. - Current assets rose to CNY 12.32 billion, compared to CNY 10.09 billion in the previous year, reflecting an increase of about 22.1%[39]. - Total liabilities reached CNY 8.97 billion, compared to CNY 7.30 billion, reflecting a growth of about 22.9%[39]. - Total liabilities rose to ¥6,824,196,053.00 in Q3 2020, compared to ¥5,606,750,173.57 in Q3 2019, an increase of 21.7%[43]. - Shareholders' equity totaled ¥4,319,251,141.23 in Q3 2020, up from ¥3,912,266,199.23 in Q3 2019, indicating a growth of 10.4%[43]. Cash Flow - The net cash flow from operating activities for the year-to-date was -¥536,566,671.10, an improvement from -¥592,361,725.67 in the previous year[16]. - The company's cash flow from operating activities for the first nine months of 2020 was ¥11,894,226,703.75, compared to ¥9,794,045,507.31 in the same period of 2019, showing a growth of approximately 21.43%[59]. - The net cash flow from operating activities for Q3 2020 was -536,566,671.10 RMB, an improvement from -592,361,725.67 RMB in Q3 2019, indicating a reduction in cash outflow[61]. - Total cash inflow from financing activities was 3,320,489,884.05 RMB, compared to 2,596,714,316.07 RMB in the same period last year, reflecting a 28% increase[63]. - Cash and cash equivalents at the end of Q3 2020 totaled 2,406,087,152.89 RMB, compared to 1,374,204,098.25 RMB at the end of Q3 2019, representing a 75% increase[63]. Investments and Expenses - Research and development expenses amounted to CNY 3,114,381.00, reflecting an increase due to higher spending by the subsidiary Xian Zhu Traditional Chinese Medicine Technology[25]. - Research and development expenses for Q3 2020 were ¥1,436,411.16, with no prior year data available for comparison[47]. - The company reported a total of ¥2,417,204.56 in non-recurring gains and losses for the year-to-date[19]. - Investment income decreased by 79.54% to CNY 2,034,131.37 from CNY 9,944,250.15, primarily due to reduced interest from structured deposits[25]. - The total cash outflow from investing activities was 631,188,941.22 RMB, down from 1,163,805,404.26 RMB in Q3 2019, indicating a decrease of about 46%[61]. Shareholder Information - The total number of shareholders at the end of the reporting period was 31,581, with the largest shareholder holding 27.86% of the shares[22]. - The company implemented a capital reserve conversion plan, increasing share capital by 40% for existing shareholders[18]. - The company's share capital increased by 39.98% to CNY 362,662,706.00 from CNY 259,073,441.00 due to capital reserve conversion[25]. Future Plans - The company plans to expand its logistics operations and traditional Chinese medicine production capabilities as part of its growth strategy[25]. - The company plans to continue its market expansion and product innovation strategies to enhance its competitive position in the pharmaceutical industry[56].